Inoxgen (Nitric Oxide)

Nitric oxide released from Inoxgen diffuses into the smooth muscle cells of the pulmonary arteries, where it activates soluble guanylate cyclase. This enzyme increases cyclic GMP levels, leading to relaxation of the vascular smooth muscle and selective vasodilation of the pulmonary circulation without causing systemic blood pressure changes.

The dose of Inoxgen is individualized and set by the prescribing clinician based on the patient’s age, weight, severity of pulmonary hypertension, and response to therapy. Dosing is typically titrated using continuous monitoring of pulmonary pressures and methemoglobin levels to achieve the desired clinical effect.

Safety data for Inoxgen in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss potential risks with the patient.

To order Inoxgen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inoxgen delivers nitric oxide directly to the lungs, providing rapid and selective pulmonary vasodilation, whereas oral or intravenous agents such as phosphodiesterase‑5 inhibitors act systemically and may have broader cardiovascular effects. Inhaled nitric oxide allows precise titration and immediate cessation if adverse effects occur.

Inoxgen cylinders should be stored at ambient temperature, away from direct sunlight and heat sources. Keep the cylinders in their original packaging, ensure they are secured upright, and follow local regulations for compressed gas handling. Do not expose the gas to temperatures above 30 °C for prolonged periods.

Inoxgen is administered via a calibrated inhalation delivery system that mixes the gas with the patient’s ventilator circuit or breathing apparatus. The clinician sets the desired concentration, typically expressed in parts per million (ppm), and monitors pulmonary pressures and methemoglobin levels throughout the treatment.

The most serious risks include severe methemoglobinemia, which can impair oxygen delivery, rebound pulmonary hypertension after abrupt discontinuation, and acute systemic hypotension. Prompt recognition and monitoring of methemoglobin levels, as well as gradual weaning of the gas, are essential to mitigate these risks.

Inoxgen should be avoided in patients with severe anemia, known hypersensitivity to nitric oxide, or those in whom rapid changes in pulmonary vascular tone could be hazardous. It is also contraindicated in individuals with significant methemoglobin reductase deficiency without close monitoring.